| Primary | The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) | The outcome measured is the percentage of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of Glabellar Lines (GL) severity at maximum frown at Day 30. The investigator and participant evaluates the participant's GL severity using a Facial Wrinkle Scale With Photonumeric Guide (FWS) at maximum frown on Day 30. The scale ranges from (0 to 3) where 0=none and 3 = severe. | All primary and secondary efficacy analyses endpoints were carried out using the Intent To Treat (ITT) analysis set, which was defined as all participants who were randomized. Multiple imputation method was used for missing variables in primary efficacy endpoint. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | The Duration of Glabellar Line (GL) Treatment in Participants Who Achieved a Rating of ≥ 2-grade Improvement From Baseline in GL Severity at Maximum Frown at Day 30 According to Investigator Assessments Using the Facial Wrinkle Scale (FWS) | The investigator evaluates the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe. The outcome is measured as median time to loss of treatment effect (ie, return to moderate or severe GL severity at maximum frown using the FWS). | The analysis population for this outcome includes the participants who achieved a rating of ≥ 2-grade improvement from baseline in GL severity at maximum frown at Day 30 according to investigator assessments using the Facial Wrinkle Scale (FWS). This corresponds to the responders for Outcome 3. NA means no participant from the group achieved a rating of ≥ 2-grade improvement from baseline in GL severity. Note: Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Median | 95% Confidence Interval | days | | Day 1 (first treatment) to Day 180 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | The Percentage of Responders for Investigator Assessments of Glabellar Lines (GL) Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS) | The percentage of Responders for Investigator Assessments of Glabellar Lines (GL) Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS), where a Responder was defined as Achieving a ≥2-grade Improvement from Baseline at Maximum Frown at Day 30. The investigator evaluates the participant's GL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. | All secondary efficacy analyses were carried out using the Intent To Treat (ITT) analysis set, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 |
|
| Secondary | The Percentage of Participants Reporting Mostly Satisfied/Very Satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 for Glabellar Lines (GL) | The Satisfaction Question 5 grades facial line treatment satisfaction on a 5-point scale (-2 to 2) where -2=Very dissatisfied and 2=Very satisfied. | All secondary efficacy analyses were carried out using the Intent To Treat (ITT) analysis set, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data | Posted | | Count of Participants | | Participants | | Day 60 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | The Percentage of Responders for Investigator Assessments of Glabellar Lines (GL) Severity at Rest Using the Facial Wrinkle Scale (FWS) | The outcome was measured Among Participants Who Were Rated At least Mild at Rest at Baseline, where a Responder was Defined as Achieving a ≥1-grade Improvement from Baseline at Day 30 The investigator evaluates the participant's GL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. | All secondary efficacy analyses were carried out using the Intent To Treat (ITT) analysis set, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Secondary Safety: Number of Patients Who Experienced an Adverse Event (AE) | This section focuses primarily on Treatment Emergent Adverse Events (TEAEs), i.e., AEs that started or worsened after the first dose of study intervention (Day 1) until up to 30 days after their last visit or study exit. The safety analyses were conducted in the Safety population. Unless otherwise noted, safety results refer to TEAEs. | All safety analyses were carried out using the Safety population, defined as participants who received at least 1 dose of study intervention. Participants were grouped based on their actual treatment received and not planned treatment. NOTE - 1 Participant randomized to 'Dose1 + Dose2' actually received treatment in the 'Dose1 + Placebo'. Therefore, the total number of participants analyzed in the 'MT10109L Dose 1 into GL + Placebo into LCL' arm is 174 instead of 173 that started in this arm. | Posted | | Count of Participants | | Participants | | The time frame for AEs is after the first dose (Day 1) and up to 30 days after their last visit or study exit (Day 360 unless participant exits earlier) | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | |
|
| Secondary | Mean Change From Baseline in Systolic Blood Pressure (BP) | Changes in vital signs: Systolic BP | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change in mmHg | | Baseline to Day 360 (Study exit) | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Diastolic Blood Pressure (BP) | Changes in vital signs: Diastolic BP | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change in mmHg | | Baseline to Day 360 (Study exit) | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Pulse Rate | Changes in vital signs: Pulse Rate | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change in beats/min | | Baseline to Day 360 (Study exit) | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Respiratory Rate | Changes in vital signs: Respiratory Rate | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change in breaths/min | | Baseline to Day 360 (Study exit) | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - Heart Rate | Change from baseline for ECG safety population - Heart Rate | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in beats/min | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - PR Interval | Change from baseline for ECG safety population - PR Interval | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QRS Duration | Change from baseline for ECG safety population - QRS duration | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QT Interval | Change from baseline for ECG safety population - QT interval | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcB Interval | Change from baseline for ECG safety population - QTcB interval | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcF Interval | Change from baseline for ECG safety population - QTcF interval | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - RR Interval | Change from baseline for ECG safety population - RR interval | All safety analyses were carried out using the Safety population, which was defined as all participants who received at least 1 dose of study intervention. In Safety population, participants were grouped based on their actual treatment received and not planned treatment. In order to calculate the mean change from baseline, participants with non-missing analysis values at both baseline and post-baseline (Day 360) during that analysis visit were used. | Posted | | Mean | Standard Deviation | Change from baseline in msec | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL) |
|
| Secondary | Number of Participants With Binding and Neutralizing Antibodies | Only samples that tested positive in the binding antibody confirmatory assay were evaluated for neutralizing antibodies. The participants with positive neutralizing antibodies are only shown. | All safety analyses were carried out using the Safety population, defined as participants who received at least 1 dose of study intervention. Participants were grouped based on their actual treatment received and not planned treatment. NOTE - 1 Participant randomized to 'Dose1 + Dose2' actually received treatment in the 'Dose1 + Placebo'. Therefore, the total number of participants analyzed in the 'MT10109L Dose 1 into GL + Placebo into LCL' arm is 174 instead of 173 that started in this arm. | Posted | | Count of Participants | | Participants | | Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Placebo was injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL) | MT10109L Dose 1 was injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 |
|